Epoch Biosciences Licenses Technologies to Celera Diagnostics
MGB(TM) Technology and Eclipse(TM) Dark Quencher to be used in Infectious Disease Products
Epoch Biosciences, Inc., a provider of proprietary products that accelerate genomic analysis, announced it has entered into a worldwide non-exclusive license with Celera diagnostics, a joint venture between the Celera Genomics Group (NYSE:CRA) and Applied Biosystems Group (NYSE:ABI) of Applera Corporation, for incorporation of its MGB(TM) Technology and Eclipse(TM) Dark Quencher Technology into Celera Diagnostics' products for selected infectious diseases.
The license allows Celera Diagnostics to manufacture, sell and distribute TaqMan® probes that utilize Epoch's minor groove binder and quencher in selected products. Under the license agreement, Epoch will receive license fees and royalties on sales of such licensed products to end users. Additional terms of the agreement were not disclosed.
William G. Gerber, M.D., chief executive officer of Epoch, said, "This agreement is a milestone for Epoch because it represents our first business agreement in the human diagnostics field. Our initial diagnostics strategy is to introduce a large portfolio of analyte-specific reagents for use by large laboratories, and during the past year we listed 17 ASRs with the FDA for the detection of infectious and inherited diseases. We plan to market many reagents directly and expect to introduce 20 in the first half of 2004, but we also intend to use partners for distribution of certain targets. The alliance between Celera Diagnostics and Abbott Laboratories, wherein Abbott distributes certain products developed and manufactured by Celera Diagnostics, is a powerful combination for accelerating the global impact of advanced molecular diagnostics."
Kathy Ordo?ez, president of Celera Diagnostics, said, "We believe Epoch's technologies can help us achieve our goal of bringing diagnostics tools and products to clinical laboratories that provide timely and actionable information to benefit their ultimate customers; the medical decision makers and patients."
Analyte-specific reagents (ASRs) are assay components used by clinical laboratories to develop assays that provide medically significant information to physicians and hospitals. ASRs are exempt from 510(k) regulations for diagnostic products, but are manufactured under cGMP guidelines and listed with the FDA. Such components can only be sold to appropriate laboratories by registered manufacturers.
MGB Technology MGB technology is based on a potent class of naturally occurring antibiotics that bind to the minor groove of double stranded DNA. When attached to either the 5' or 3' terminus of DNA probes, hydrophobic binding of MGB molecules to the minor groove stabilizes DNA duplexes formed by these probes hybridizing to their complementary targets. This allows the use of shorter probes with higher sensitivity to mismatches, which is particularly beneficial in the design of probes for the analysis of single nucleotide polymorphisms (SNP) or short, conserved sequences of viral genomes or multi- gene families for which limited target sequence is available. Epoch Biosciences was the first to recognize and utilize the enhanced performance and expanded assay design flexibility that MGB technology provides for DNA probe based detection systems.
MGB is currently incorporated into MGB Eclipse(TM) Probe Systems sold by Epoch and in TaqMan® products sold by Applied Biosystems in the research field, and in BioControl System's food testing products.
Eclipse Dark Quencher Technology The Eclipse Dark Quencher is a pioneering technology developed by Epoch Biosciences that when attached with a fluorescent dye to a DNA probe, suppresses the signal generated by the dye until the probe binds to its target DNA. It offers higher sensitivity in real-time PCR probes due to lower background fluorescence, is applicable in a broad range of detection systems, quenches a broader dye emission spectra range, and is compatible with simple and robust DNA synthesis procedures.
The Eclipse Dark Quencher is currently incorporated into MGB Eclipse Probe Systems sold by Epoch, in other TaqMan products sold by Applied Biosystems, in the Invader System sold by Third Wave Technologies, and in QuantiTect(TM) gene expression assays sold by QIAGEN. The Eclipse Dark Quencher is also licensed to Applied Biosystems for use in environmental testing products and to Takara for use in real-time PCR detection assays, and is distributed by Glen Research for sale into the research community.
Other news from the department business & finance
These products might interest you
Micro-Dx™ CE IVD by Molzym
Fully automated from sample to PCR analysis
Rapid identification of bacteria and fungi without time-consuming cultivation
DNA-free Taq Polymerases and Mastermixes by Molzym
DNA-free reagents for unrivalled sensitivity in molecular biology
Purity that makes the difference
Greener Alternative Products by Merck Life Science
Sustainable laboratory products for environmentally conscious research
Over 2,500 ecological alternatives to reduce your laboratory footprint
CellGenix® Growth Factors and Cytokines by Sartorius
Recombinant growth factors without animal products
Optimised cell culture for T cells and MSCs in gene therapy
Recombumin® Elite by Sartorius
ICHQ7 cGMP-compliant albumin for biotechnological applications
Increase consistency and safety for gene therapies and vaccines
DNA/RNA Shield™ SafeCollect Collection Kits by Zymo Research
Sample collection devices for simple & safe at-home testing
Best user experience for secure self-collection
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
